|
Federal
Register Notices > Rules - 200 9
>
Registration Requirements for Individual Practitioners
Operating in a "Locum Tenens" Capacity
9
FR Doc E9-25937[Federal Register: October 28, 2009 (Volume
74, Number 207)] [Proposed Rules] [Page 55499-55502] From the
Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr28oc09-24]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1301
[Docket No. DEA-324a] RIN 1117-AB21
Registration Requirements for Individual Practitioners
Operating in a "Locum Tenens" Capacity
AGENCY: Drug Enforcement Administration (DEA),
Department of Justice.
ACTION: Advance notice of proposed rulemaking.
Summary: On December 1, 2006, the Drug Enforcement
Administration (DEA) published in the Federal Register a Final
Rule "Clarification of Registration Requirements for
Individual Practitioners" (71 FR 69478). The Final Rule
makes it clear that when an individual practitioner practices in
more than one State, he or she must obtain a separate DEA
registration for each State. The Final Rule also noted that DEA
would address its policy regarding locum tenens practitioners in
a separate future document. To adequately address this issue,
DEA is publishing this Advance Notice of Proposed Rulemaking to
seek information useful to the agency in promulgating
regulations regarding locum tenens practitioners.
DATES: Written comments must be postmarked on or
before December 28, 2009, and electronic comments must be sent
on or before midnight Eastern time December 28, 2009.
ADDRESSES: To ensure proper handling of comments,
please reference "Docket No. DEA-324" on all written
and electronic correspondence. Written comments being sent via
regular or express mail should be sent to the Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODL,
8701 Morrissette Drive, Springfield, VA 22152. Comments may be
sent to DEA by sending an electronic message to
dea.diversion.policy@usdoj.gov. Comments may also be sent
electronically through http://www.regulations.gov using the
electronic comment form provided on that site. An electronic
copy of this document is also available at the http://www.regulations.gov
Web site. DEA will accept attachments to electronic comments in
Microsoft Word, WordPerfect, Adobe PDF, or Excel file formats
only. DEA will not accept any file formats other than those
specifically listed here.
Please note that DEA is requesting that electronic comments
be submitted before midnight Eastern Time on the day the comment
period closes because http://www.regulations.gov terminates the
public's ability to submit comments at midnight Eastern Time on
the day the comment period closes. Commenters in time zones
other than Eastern Time may want to consider this so that their
electronic comments are received. All comments sent via regular
or express mail will be considered timely if postmarked on the
day the comment period closes.
FOR FURTHER INFORMATION CONTACT: Mark W. Caverly,
Chief, Liaison and Policy Section, Office of Diversion Control,
Drug Enforcement Administration, 8701 Morrissette Drive,
Springfield, VA 22152; telephone: (202) 307-7297.
SUPPLEMENTARY INFORMATION: Posting of Public Comments:
Please note that all comments received are considered part of
the public record and made available for public inspection
online at http://www.regulations.gov and in the Drug Enforcement
Administration's public docket. Such information includes
personal identifying information (such as your name, address,
etc.) voluntarily submitted by the commenter.
If you want to submit personal identifying information (such
as your name, address, etc.) as part of your comment, but do not
want it to be posted online or made available in the public
docket, you must include the phrase "PERSONAL IDENTIFYING
INFORMATION" in the first paragraph of your comment. You
must also place all the personal identifying information you do
not want posted online or made available in the public docket in
the first paragraph of your comment and identify what
information you want redacted.
If you want to submit confidential business information as
part of your comment, but do not want it to be posted online or
made available in the public docket, you must include the phrase
"CONFIDENTIAL BUSINESS INFORMATION" in the first
paragraph
[[Page 55500]]
of your comment. You must also prominently identify
confidential business information to be redacted within the
comment. If a comment has so much confidential business
information that it cannot be effectively redacted, all or part
of that comment may not be posted online or made available in
the public docket.
Personal identifying information and confidential business
information identified and located as set forth above will be
redacted and the comment, in redacted form, will be posted
online and placed in the Drug Enforcement Administration's
public docket file. Please note that the Freedom of Information
Act applies to all comments received. If you wish to inspect the
agency's public docket file in person by appointment, please see
the "For Further Information" paragraph.
DEA's Legal Authority
DEA implements and enforces the Comprehensive Drug Abuse
Prevention and Control Act of 1970, often referred to as the
Controlled Substances Act (CSA) and the Controlled Substances
Import and Export Act (CSIEA), (21
U.S.C. 801-971), as amended. DEA publishes the implementing
regulations for these statutes in Title 21 of the Code of
Federal Regulations (CFR), Parts 1300 to end. These regulations
are designed to ensure that there is a sufficient supply of
controlled substances for medical, scientific, and other
legitimate purposes and to deter the diversion of controlled
substances to illegal purposes.
Controlled substances are drugs that have a potential for
abuse and psychological and physical dependence; these include
substances classified as opioids, stimulants, depressants,
hallucinogens, anabolic steroids, and drugs that are immediate
precursors of these classes of substances. DEA lists controlled
substances in 21
CFR part 1308. The substances are divided into five
schedules: Schedule I substances have a high potential for abuse
and have no accepted medical use in treatment in the United
States. These substances may only be used for research, chemical
analysis, or manufacture of other drugs. Schedule II-V
substances have an accepted medical use and also have a
potential for abuse and psychological and physical dependence.
The CSA mandates that DEA establish a closed system of
control for manufacturing, distribution, and dispensing of
controlled substances. Any person who manufactures, distributes,
dispenses, imports, exports, or conducts research or chemical
analysis with controlled substances must register with DEA
(unless exempt), keep track of all stocks of controlled
substances, and maintain records to account for all controlled
substances received, distributed, dispensed, or otherwise
disposed of.
Background
The CSA defines "dispense" as meaning "to
deliver a controlled substance to an ultimate user or research
subject by, or pursuant to the lawful order of, a practitioner,
including the prescribing and administering of a controlled
substance * * *" (21
U.S.C. 802(10)). The CSA requires that every person who
dispenses controlled substances shall obtain from the Attorney
General a registration (21
U.S.C. 822(a)(2)). Authority to issue such registrations has
been delegated by the Attorney General to the Administrator of
the Drug Enforcement Administration (28 CFR 0.100). DEA has
established, by regulation, that the period of registration for
persons who dispense controlled substances is three years (21
CFR 1301.13(e)(iv)).
The CSA states that the Attorney General shall register
practitioners to dispense controlled substances if the applicant
for registration is authorized to dispense controlled substances
under the laws of the State in which the applicant practices (21
U.S.C. 823(f)). The Attorney General may deny an application
for registration if he determines that the issuance of
registration would be inconsistent with the public interest. In
determining the public interest, the Attorney General is
required to consider the following factors:
(1) The recommendation of the appropriate State licensing
board or professional disciplinary authority.
(2) The applicant's experience in dispensing, or conducting
research with respect to controlled substances.
(3) The applicant's conviction record under Federal or
State laws relating to the manufacture, distribution, or
dispensing of controlled substances.
(4) Compliance with applicable State, Federal, or local
laws relating to controlled substances.
(5) Such other conduct which may threaten the public health
and safety. (21 U.S.C. 823(f))
The CSA further requires that a separate registration be
obtained for each principal place of business or professional
practice where controlled substances are manufactured,
distributed, or dispensed (21
U.S.C. 822(e)). DEA has provided a limited exception to this
requirement (21 CFR 1301.12(b)(3)): Practitioners who register
at one location, but practice at other locations within the same
State, are not required to register for any other location in
that State at which they only prescribe controlled substances.
The exception applies only to additional locations within the
same State in which the practitioner maintains his DEA
registration. DEA individual practitioner registrations are
based on a State license to practice medicine and prescribe
controlled substances. DEA relies on State licensing boards to
determine that practitioners are qualified to administer,
dispense, or prescribe controlled substances and to determine
what level of authority practitioners have, that is, what
schedules they may administer, dispense, or prescribe. State
authority to conduct the above-referenced activities only
confers rights and privileges within the issuing State;
consequently, the DEA registration based on a State license
cannot authorize controlled substance dispensing outside the
State.
DEA discussed the intrastate exception extensively in a
Notice of Proposed Rulemaking "Clarification of
Registration Requirements for Individual Practitioners"
[Docket No. DEA-244, RIN 1117-AA89] (69 FR 70576, December 7,
2004) and in a subsequent Final Rule (71 FR 69478, December 1,
2006). This rule clarified that the exception discussed above
related only to intrastate, as opposed to interstate, locations.
Locum Tenens Practitioners
DEA received three comments to its December 7, 2004, Notice
of Proposed Rulemaking requesting clarification of the effect of
that rule on the practice of "locum tenens"
practitioners. Locum tenens is a procedure whereby someone
substitutes temporarily for another. Latin for "to hold the
place of, to substitute for," locum tenens means, in
layman's terms, a temporary physician or other practitioner.
Usually, locum tenens practitioners contract with a staffing
company to perform medical services for a healthcare
organization for a specified length of time. The practitioner is
paid by the staffing firm itself, which is then paid by the
healthcare facility, i.e., the client.
Groups supportive of locum tenens indicate that the practice
of locum tenens benefits both practitioners and healthcare
organizations because it provides flexibility for both parties.
They note that the industry offers temporary opportunities for
medical professionals across the country and worldwide. DEA has
found one estimate indicating that there are over 100 locum
tenens agencies operating in the United States and over 30,000
locum tenens practitioners. The practitioners in
[[Page 55501]]
demand are hospital-based specialties including
anesthesiology, psychiatry, radiology, pediatrics, and surgery.
The CSA does not specifically reference or acknowledge the
practice of locum tenens. DEA regulations do make clear that
under 21
CFR 1301.12(a), "A separate registration is required
for each principal place of business or professional practice at
one general physical location where controlled substances are
manufactured, distributed, imported, or dispensed by a
person." When a locum tenens practitioner substitutes for
another practitioner on a temporary or sporadic basis at that
other practitioner's [DEA registered] place of business, that
place of business is considered by DEA to be a "principal
place of business or professional practice" for purposes of
the locum tenens practitioner's DEA registration (21 CFR
1301.12(a)).
Since DEA individual practitioner registrations are based on
State authority to practice and prescribe controlled substances,
a practitioner is not authorized to dispense controlled
substances outside the State(s) in which he or she is licensed
and registered. Therefore, any locum tenens practice that is
conducted in a State other than the State in which the
practitioner maintains his DEA registration is subject to a
separate DEA registration.
DEA believes that two alternatives presently exist to obtain
a separate DEA registration in another State to accommodate a
locum tenens practice. First, if the practitioner is licensed to
practice and to handle controlled substances in that second
state, he may submit an address change for his current DEA
registration for the temporary practice location. There is no
cost to change an address, even temporarily, and it generally
takes one week to process. At the end of the locum tenens
practice, the practitioner may submit a request to change his
address to his new primary place of business, within the same
state.
Second, if the locum tenens service is with a hospital or
other institution registered with DEA, if the hospital agrees,
and if State law allows, the practitioner may use the DEA
registration of that hospital or other institution to
administer, dispense, or prescribe controlled substances so long
as all requirements are met (21
CFR 1301.22(c)). Specifically:
An individual practitioner who is an agent or employee of a
hospital or other institution may, when acting in the normal
course of business or employment, administer, dispense, or
prescribe controlled substances under the registration of the
hospital or other institution which is registered in lieu of
being registered himself, provided that:
(1) Such dispensing, administering or prescribing is done
in the usual course of his professional practice;
(2) Such individual practitioner is authorized or permitted
to do so by the jurisdiction in which he is practicing;
(3) The hospital or other institution by whom he is
employed has verified that the individual practitioner is so
permitted to dispense, administer, or prescribe drugs within
the jurisdiction;
(4) Such individual practitioner is acting only within the
scope of his employment in the hospital or institution;
(5) The hospital or other institution authorizes the
individual practitioner to administer, dispense or prescribe
under the hospital registration and designates a specific
internal code number for each individual practitioner so
authorized. The code number shall consist of numbers, letters,
or a combination thereof and shall be a suffix to the
institution's DEA registration number, preceded by a hyphen
(e.g., APO123456-10 or APO123456-A12); and
(6) A current list of internal codes and the corresponding
individual practitioners is kept by the hospital or other
institution and is made available at all times to other
registrants and law enforcement agencies upon request for the
purpose of verifying the authority of the prescribing
individual practitioner. (21
CFR 1301.22(c))
This waiver places the controlled substance registration and
recordkeeping responsibility with the hospital or other
institution; therefore, there is no need for individual DEA
registration. However, the individual practitioner must still
maintain State licensure.
State Regulations
As DEA discussed in its proposed and final rules regarding
the clarification of registration by individual practitioners
(69 FR 70576, December 7, 2004; 71 FR 69478, December 1, 2006),
the issuance by DEA of an individual practitioner registration
is predicated, in part, on the practitioner being authorized
(e.g., licensed) to dispense controlled substances by the State
in which he practices (21
U.S.C. 823(f)). Valid State authority to dispense controlled
substances is a necessary, but not sufficient, condition for
obtaining a DEA registration. DEA will not register a
practitioner at a particular location within a State if the
practitioner lacks valid State authority to dispense controlled
substances in that State. DEA registration serves, in part, to
reflect that the individual practitioner has been granted some
level of controlled substances authority by the State. In light
of the above, a DEA registration is considered to be related
directly and exclusively to the license issued to the
practitioner by the State in which he maintains the
registration. These principles are discussed extensively in
DEA's proposed and final rules referenced above.
While DEA is aware that a few States have legislation or
regulations regarding the locum tenens industry, DEA does not
believe that the information it has regarding States'
legislation and/or regulations is complete. DEA notes that
States may address locum tenens under general legislative
authority and through a variety of State regulatory entities,
including State boards of medicine and State licensing
commissions. Therefore, as discussed further below, DEA is
specifically seeking information from State regulatory
authorities regarding States' legislative and/or regulatory
requirements for locum tenens practitioners, agencies, and
entities that contract with these persons.
Comments Requested
DEA is soliciting information from the locum tenens industry
so that DEA may obtain a better understanding of this industry
and how it functions. DEA seeks to clarify the requirements that
apply to locum tenens practitioners, especially after
considering the December 2006 final rule that specified that
only intrastate locations are subject to the exception for
registration at separate locations. Commenters are encouraged to
include the comment number enumerated below in their response.
Although all comments are welcome, DEA is particularly
interested in comments regarding the questions listed below.
These questions are separated into groups by area of
interest.
The groups are:
- Locum tenens practitioners
- Those that employ and place locum tenens
practitioners
- Institutions that retain the services of locum tenens
practitioners
- State regulatory authorities
Locum Tenens Practitioners
1. In your experience, what types of practitioners
participate in locum tenens activities (e.g., physicians,
dentists, nurse practitioners)? Please specify your type of
licensure.
2. How long is the typical locum tenens assignment?
3. Do locum tenens practitioners seek State/Federal
licensure or registration prior to accepting a position as a
locum tenens practitioner?
4. What is the length of time between hiring for the
position and reporting to duty?
5. Do practitioners secure locum tenens positions
independently or through an agency?
[[Page 55502]]
6. As locum tenens practitioners, do you administer,
dispense and prescribe controlled substances? Does your
authority to do so vary in the States in which you practice?
7. Can you have more than one locum tenens job at a time?
Those That Employ and Place Locum Tenens Practitioners
8. What role do you have in the locum tenens process?
9. Do you assist with State and Federal
licensure/registration? If so, how?
10. What types of practitioners do you employ or place
(e.g., physicians, dentists, nurse practitioners)?
11. How do you verify the locum tenens practitioner's
credentials?
12. Are criminal background checks performed on locum
tenens practitioners?
13. What is the geographical coverage for locum tenens
(e.g., local, statewide, multi-state, national)?
14. How much time is there between assignments for one
practitioner?
Institutions That Retain the Services of Locum Tenens
Practitioners
15. How many locum tenens placement agencies do you
contract with?
16. How frequently do you secure locum tenens services?
17. What credentialing checks do you perform on the locum
tenens practitioners working for you? Do you perform fewer
checks for practitioners supplied by agencies than you do for
practitioners you contract with individually?
18. For how long do you secure locum tenens services (i.e.,
duration)?
19. For what specialties do you use locum tenens
practitioners?
20. What authority do you grant locum tenens practitioners?
(For example, can they administer, dispense, or prescribe
controlled substances? Under whose DEA registration would such
an activity occur?)
21. Do you grant locum tenens practitioners the same
controlled substance authority that other practitioners using
the institution's DEA registration to dispense controlled
substances have? If not, why not?
State Regulatory Authorities
22. What are the State requirements for locum tenens
practice for practitioners (e.g., physicians, dentists)?
23. Does the State waive State medical licensure (or
automatically grant temporary courtesy licensure) for locum
tenens practitioners if they are properly licensed in another
State? If so, what checks are performed to confirm State
licensure in the other State?
24. If granted, for how long is the waiver or courtesy
licensure?
25. What are the State requirements for locum tenens
practice for mid-level practitioners (e.g., physician
assistants, nurse practitioners)?
26. Does the State waive State licensure (or automatically
grant temporary courtesy licensure) for locum tenens
practitioners who are mid-level practitioners if they are
properly licensed in another State? If so, what checks are
performed to confirm State licensure in the other State?
27. If granted, for how long is the waiver or courtesy
licensure?
28. If the State requires State licensure with the medical
or other professional board, how long is it good for?
29. Does the State grant locum tenens practitioners the
same controlled substance authority that it grants to
practitioners that are fully licensed by the State
professional board? If not, why not?
30. To dispense controlled substances, must a locum tenens
practitioner obtain a State controlled substance registration?
31. Does the State medical or other professional board
report board actions against locum tenens practitioners to the
National Practitioner database and to States in which the
locum tenens practitioner holds a license?
Regulatory Certifications
This action is an Advance Notice of Proposed Rulemaking (ANPRM).
Accordingly, the requirement of Executive Order 12866 to assess
the costs and benefits of this action does not apply. Rather,
among the purposes DEA has in publishing this ANPRM is to seek
information from the public regarding locum tenens
practitioners. Similarly, the requirements of section 603 of the
Regulatory Flexibility Act do not apply to this action since, at
this stage, it is an ANPRM and not a "rule" as defined
in section 601 of the Regulatory Flexibility Act. Following
review of the comments received to this ANPRM, if DEA
promulgates a Notice or Notices of Proposed Rulemaking regarding
this issue, DEA will conduct all analyses required by the
Regulatory Flexibility Act, Executive Order 12866, and any other
statutes or Executive Orders relevant to those rules and in
effect at the time of promulgation.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion
Control.
[FR Doc. E9-25937 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|